The addition of nivolumab to tivozanib after prior immune checkpoint inhibitor is not superior to standard dose tivozanib alone prnewswire.com/news-releases/…

Proud to share our paper Journal of Clinical Investigation led by ShengYu Ku Dana-Farber with #GoodrichLab Roswell Park: Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer PCF Science jci.org/articles/view/…

How would you treat an oligometastatic #RCC patient, eligible for resection of all disease? Please RT Shilpa Gupta Sumanta K. Pal, MD, FASCO Brian Rini, MD Toni Choueiri, MD Robert Motzer MD Tom Powles Elizabeth Plimack MD Tian Zhang, MD, MHS Pedro C Barata, MD MSc FACP Enrique Grande Daniel Castellano FLoscoMD Martín Angel Yüksel Ürün

CHMP gives a positive recommendation for Enfortumab Vedotin and Pembrolizumab in 1st line advanced UC. Paving the way for use in Europe. merck.com/news/merck-rec…

📰 Exciting news from EORTC! 🎉 OncoAlert 🔹 EORTC-1333-GUCG/PEACE III trial has reached its primary endpoint. 🔹 Compared enzalutamide vs. enzalutamide + radium-223 in asymptomatic or mildly symptomatic castration-resistant prostate cancer patients metastatic to bone. 🔹 Full

From foes to friends: rethinking the role of lymph nodes in prostate cancer out on Nature Reviews Urology nature.com/articles/s4158… The therapeutic value of lymph node removal in prostate cancer treatment is debated, as while it aids in disease staging, it may reduce the effectiveness of

Testicular Germ Cell Tumors with Venous Tumor Thrombus: Prevalence, Presentation, and Management Eur Urol Focus Sarah P. Psutka MD MS Philippe spiess Global Society of Rare GU Tumors eu-focus.europeanurology.com/article/S2405-…

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

🔝🔝🔝🎓Beautiful article, you must read it!! 💫🌟🔍 INDUCOMAIN Study: Evaluation of avelumab plus chemotherapy in cisplatin-ineligible metastatic urothelial carcinoma.🌟💫 Bego PValderrama Daniel Castellano Álvaro Pinto Javier Puente, Dr. E. Gonzalez-Billalabeitia, joaquim bellmunt. SOGUG

💉Vacunación en pacientes con #Cancer 💡Fundamental saber cuál, cuando y como aplicarlas Preceptoría de #Vacunas de la Asociación Argentina de Oncología Clínica (AAOC) + Sociedad Argentina Infectología

A very important and practice-informing trial dealing with HIF2 inhibitor Belzutifan dose in RCC. More is not better ! Congrats Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute and team! Bravo !

Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria Andrea Apolo, M.D. Shilpa Gupta joaquim bellmunt Jonathan Rosenberg MD Michiel van der Heijden & Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…

Thoracic Surgery and Oncology always working together in HCSC!! #WCLC2024 Carlos Alfredo Fraile Olivero jlgonzalezlarriba #martaamman OncomedHCSC José Ramón Jarabo

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

#ESMO24 Tom Powles has presented another practice changing bladder trial!! periop GC+Durva, meets EFS+OS NIAGARA trial Congrats!!!!!

Javier Puente Tom Powles Excellent data!! And now, let’s go for bladder preserving approaches!!!

Discussing the GU Oncology highlights at #ESMO2024 with our reporters De Maeseneer Daan and Javier Puente. ✍️Our medical writers will “lock themselves up” in the coming days to prepare slides on #ProstateCancer, #BladderCancer and #RenalCellCarcinoma highlights with impact on clinical

Save the date for #ESMO25 in Berlin! Honored to be the Scientific co-Chair with Myriam Chalabi —Stay tuned for the ESMO - Eur. Oncology program!

Efficacy and safety of darolutamide + ADT vs ADT in pts in mHSPC #ProstateCancer from the phase 3 ARANOTE trial ESMO - Eur. Oncology #ESMO24 by • 👉rPFS, the primary endpoint met (HR:0.54), PSA<0.2 ng/ml anytime occurred in 62%. PCF Science UroToday.com OncoAlert

Potential biomarkers in PCa by niven mehra Data form P3 are still lacking Let’s move to the next generation of trials #ESMO24